I farmaci anti-obesità in età evolutiva
Contenuto principale dell'articolo
Abstract
È stato dimostrato che l'uso di agonisti del GLP-1 riduce il peso e migliora il controllo glicemico nei bambini, agendo attraverso la riduzione dell'appetito e il rallentamento dello svuotamento gastrico. Gli agonisti del GLP-1 agiscono a livello cerebrale stimolando specifici recettori in aree del sistema nervoso centrale, come l'ipotalamo, inducendo così un maggiore senso di sazietà. Influenzano inoltre la funzionalità gastrointestinale rallentando lo svuotamento gastrico, il che contribuisce a contenere l'aumento post-prandiale dei livelli di lipidi e carboidrati.
Gli agonisti dei recettori del peptide-1 simile al glucagone (agonisti del GLP-1) si sono rivelati un'opzione terapeutica promettente per i pazienti pediatrici, grazie ai loro effetti benefici sulla riduzione del peso e sulla regolazione glicemica. Sono necessari ulteriori studi per valutarne la sicurezza a lungo termine in relazione alla crescita, alla pubertà e allo sviluppo osseo.
Il loro impiego deve essere personalizzato e integrato con programmi di terapia comportamentale, nutrizione e attività fisica. Nel complesso, l'efficacia degli agonisti del GLP-1 nel controllo glicemico di bambini e adolescenti affetti da diabete mellito di tipo 2 è ben documentata. Pertanto, tali farmaci rappresentano una valida terapia aggiuntiva per i giovani con diabete mellito di tipo 2 che non raggiungono un controllo glicemico ottimale con la sola metformina o insulina.
Downloads
Dettagli dell'articolo

Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.
Riferimenti bibliografici
Torbahn G, Jones A, Griffiths A, et al. Pharmacological interventions for the management of children and adolescents living with obesity—An update of a Cochrane systematic review with meta-analyses. Pediatric Obesity. 2024; 19(5):e13113.
Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther. (2011) 90:164–8.
World Health Organization . Spotlight on Adolescent Health and Well-Being: Findings from the 2017/2018 Health Behaviour in School-Aged Children (HBSC) Survey in Europe and Canada. World Health Organization; Copenhagen, Denmark: 2020.
Pasquali R, Casanueva F, Haluzik M, et al. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur J Endocrinol 2020; 182: G1-G32.
Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102: 709-57.
Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 2023; 151: e2022060640.
Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 2023; 151(2):e2022060640
Llewellyn A, Simmonds M, Owen CG, et al. Childhood obesity as a predictor of morbidity in adulthood: a systematic review and meta-analysis. Obes Rev 2016; 17: 56-67.
Reilly JJ, Wilson O. ABC of obesity. Childhood obesity. BMJ 2006; 333: 1207-10.
Valerio G, Maffeis C, Saggese G, et al. Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics. Ital J Pediatr 2018; 44: 88.
https://www.siedp.it/files/Doc.ConsensusObesita__2017.pdf
Lassale C, Fitó M, Morales-Suárez-Varela M, et al. Mediterranean diet and adiposity in children and adolescents: a systematic review. Obes Rev 2022; 23: e13381.
Verduci E, Bronsky J, Embleton N, et al. Role of dietary factors, food habits, and lifestyle in childhood obesity development: a position paper from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 2021; 72: 769-83.
Torbahn G, Jones A, Griffiths A, et al. Pharmacological interventions for the management of children and adolescents living with obesity—An update of a Cochrane systematic review with meta-analyses. Pediatric Obesity. 2024; 19(5):e13113.
Holst J.J. The Physiology of Glucagon-like Peptide 1. Physiol. Rev. 2007;87:1409– 1439
Jastreboff AM, Kushner RF. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annu Rev Med. 2023;74:125–39.
Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5–21.
Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol 2016; 310: R885-895.
Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med 2020; 382: 2117-28.
Bensignor MO, Bomberg EO, Bramante CT, et al. Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: post hoc analysis of the ellipse trial. Pediatr Obes 2021; 16: e12778.
Ryan PM, Seltzer S, Hayward NE, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis. J Pediatr 2021; 236: 137-47.e13.
Svensson CK, Larsen JR, Vedtofte L, et al. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand 2019; 139: 26-36.
Mysliwczyk, D.; Gofron, K.K.; Wasilewski, A.; Mysliwiec, M.; Wasilewska, E. GLP- 1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions—A Systematic Review. Nutrients 2026, 18, 1662.
Gabriel Torbahn, Julia Lischka, et al. Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps. Clin Endocrinol (Oxf). 11 settembre 2024;102(1):51–61.
Gofron K.K., Wasilewski A., Malgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17:1303).
Qirong Chen, Haixia Liu Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials. BMC Endocr Disord. 2026 marzo 30;26:132)
Ryan N, Savulescu J. The ethics of Wegovy: promoting autonomy in pediatric care. Med Health Care Philos. 2026 Mar;29(1):243-255. doi: 10.1007/s11019-025- 10300-8.
Van Geelen, Stefan M., L. E. Ineke, H. Bolt, Olga, van der Baan-Slootweg, J. H. Marieke, and van Summeren. 2013. The controversy over pediatric bariatric surgery. Journal of Bioethical Inquiry 10:227–237.
Hampl, Sarah E., G. Sandra, Asheley C. Hassink, Sarah C. Skinner, Sarah E. Armstrong, Christopher F. Barlow, C. Bolling, Kimberly, Avila, and Edwards et al. 2023. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 151:e2022060640.
Shanouda, Fady, Michael Orsini. 2023. Ozempic: The miracle drug and the harmful Idea of a future without fat. The Conversation.
Cooper, Dan M., Mark A. Rothstein, Alpesh Amin, and Jan D. Hirsch, Emma Cooper. 2023. Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action. Journal of Clinical and Translational Science 7:e184.
Mirghani H, Albishi L and Alblewi SM (2026) Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review. Front. Endocrinol. 17:1777907.
Study Group TODAY, Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. (2021) 385:416–26.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. (2021) 46:101102.
Bacha F. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children. Lancet Child Adolesc Health. (2019) 3:595–7.
Berman C, Vidmar AP, Chao LC. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes in youth. touchREV Endocrinol. (2023) 19:38–45
Amatruda M, Gembillo G, Giuffrida AE, Santoro D, Conti G. The aggressive diabetic kidney disease in youth-onset type 2 diabetes: pathogenetic mechanisms and potential therapies. Med (Kaunas). (2021) 57:868.